As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.
Full study details on clinicaltrials.gov
Name of PARP Inhibitor used in study:
Patients with a BRCA-related malignancy and/or:
Patients who refuse BRCA testing not allowed unless they have another acceptable histology
May have brain metastases that have been treated and stable for 2 months
Type of study:
Patients receive oral veliparib twice daily and oral capecitabine twice daily on 1-7 and 15-21, and oxaliplatin IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
University of Wisconsin Hospital and Clinics
Contact: George Wilding 608-263-3961 firstname.lastname@example.org